BSc (Jilin University, China), MSc (Jilin University, China), PhD (University of Sydney, Australia), Fellow of Royal Australian Chemical Institute
Dr. Jun Zeng has been involved in drug discovery and development for over 20 years in both Academic Institutions and commercial environments. He has published over 50 peer reviewed papers, one monograph, and been granted over 10 discovery patents with outstanding commercial outcomes. In 2006, one discovery patent (Selective Kinase Inhibitors) has led Cytopia Ltd to form a commercial collaboration deal with Novartis Pharma for Milestone payment up to $265Million with US$13Million upfront fee. He is a co-inventor on intellectual property associated with momelotinib; momelotinib later became the major late-stage asset in Sierra Oncology, which GSK acquired for approximately US$1.9 billion in 2022. Momelotnib was approved by FDA for the treatment of myelofibrosis, a myeloproliferative bone marrow disorder in 2023. Since 2009, he has found and co-found several companies in drug design and discovery. He is also a guest professor at Sichuan University, China and Honorable Associate Professor at University of Melbourne, Australia.